The pipeline for cell and gene therapies (CGT) is booming. Over 650 products are in phase II and beyond.¹ While most CGT products today are for oncological and hematological conditions, many pipeline therapies are expanding into other areas. Cell and gene therapies are in development for use in specialties like neurology and cardiology, where providers have limited experience with such treatments. For example, cell therapies for amyotrophic lateral sclerosis (ALS) and gene therapies for coronary artery disease (CAD) are in phase III clinical trials.¹